1-4 of 4
Deborah Hunter
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Primary Analysis Results from an Open-Label Phase II Study of INCB039110, a Selective JAK1 Inhibitor, in Patients with Myelofibrosis

John O Mascarenhas, MD MS, Moshe Talpaz, Vikas Gupta, MD FRCP, FRCPath, Lynda M Foltz, MD FRCP, Michael R Savona, MD, Ron Paquette, MD, Robert Turner, MD, Paul Coughlin, PhD MBBS, Elliott Winton, MD, Deborah Hunter, PhD, Albert Assad, MD, Jason Clark, PhD, Peter O'Neill, MBA, CCRP, Ronald Hoffman, MD, Srdan Verstovsek, MD PhD
Journal: Blood
Blood (2014) 124 (21): 714.
https://doi.org/10.1182/blood.V124.21.714.714
Published: 2014
Journal Articles

The Efficacy and Safety of Continued Hydroxyurea Therapy Versus Switching to Ruxolitinib in Patients with Polycythemia Vera: A Randomized, Double-Blind, Double-Dummy, Symptom Study (RELIEF)

Ruben Mesa, MD, Alessandro M. Vannucchi, MD, Abdulraheem Yacoub, MD MB, Pierre Zachee, MD PhD, Mamta Garg, MD FRCP, FRCPath, Roger Lyons, MD, Silwan Chedid, MD, Steffen Koschmieder, MD, Ciro Rinaldi, MD PhD, Jennifer Byrne, MB, ChB, PhD FRCP, FRCPath, Yasmin Hasan, MD, Francesco Passamonti, MD, Srdan Verstovsek, MD PhD, Deborah Hunter, PhD, Mark M Jones, MD, Shui He, PhD, Alex Morozov, MD PhD, Bruno Martino, MD
Journal: Blood
Blood (2014) 124 (21): 3168.
https://doi.org/10.1182/blood.V124.21.3168.3168
Published: 2014
Journal Articles

An Open-Label, Phase II Study Of The JAK1 Inhibitor INCB039110 In Patients With Myelofibrosis

John Mascarenhas, MD, Moshe Talpaz, MD, Vikas Gupta, MD, FRCP, FRCPath, Michael Savona, MD, FACP, Paul Coughlin, FRACP, PhD, Elliott Winton, MD, Deborah Hunter, PhD, Bijoyesh Mookerjee, MD, FACP, Lance Leopold, MD, Jason Clark, PhD, Peter O'Neill, MBA, CCRP, Ronald Hoffman, MD, Srdan Verstovsek, MD, PhD
Journal: Blood
Blood (2013) 122 (21): 663.
https://doi.org/10.1182/blood.V122.21.663.663
Published: 2013
Journal Articles

INCB018424, a Selective JAK1/2 Inhibitor, Significantly Improves the Compromised Nutritional Status and Frank Cachexia in Patients with Myelofibrosis (MF).

Ruben A. Mesa, MD, FACP, Srdan Verstovsek, Hagop M. Kantarjian, MD, Animesh D. Pardanani, MBBS, PhD, Steven Friedman, MD, Robert Newton, Susan Erickson-Viitanen, Deborah Hunter, John Redman, MD, Swamy Yeleswaram, Edward Bradley, MD, Ayalew Tefferi, MD
Journal: Blood
Blood (2008) 112 (11): 1760.
https://doi.org/10.1182/blood.V112.11.1760.1760
Published: 2008